DelveInsight's Pulmonary Arterial Hypertension pipeline report provides comprehensive insights into the pipeline landscape for 55+ companies and 55+ pipeline drugs in Pulmonary Arterial Hypertension. It includes clinical and nonclinical stage products in the pipeline drug profiles.
Some of the Key Highlights from the Pulmonary Arterial Hypertension Pipeline Report
-
There are currently 55+ drugs in the Pulmonary Arterial Hypertension pipeline.
-
The Pulmonary Arterial Hypertension pipeline comprises therapies that are in different stages of the clinical phase include Sotatercept, Seralutinib, BIA 5-1058, PF-06842874, AER-901, Belapectin, and others and are expected to be available for Pulmonary Arterial Hypertension treatment soon.
-
Several pharmaceutical companies are evaluating their drug candidates for Pulmonary Arterial Hypertension treatment include Acceleron Pharma, Bristol Myers Squibb, Gossamer Bio, Bial, Pfizer, Aerami Therapeutics, Galectin Therapeutics, among others.
-
Sotatercept (Acceleron Pharma/Bristol Myers Squibb) has received Orphan Drug and Breakthrough Therapy designations from the US Food and Drug Administration (FDA) for the treatment of Pulmonary Arterial Hypertension while the European Medicines Agency (EMA) has designated sotatercept as a Priority Medicine (PRIME) for the treatment of Pulmonary Arterial Hypertension.
-
Some other pipeline therapies in the late-stage clinical development for Pulmonary Arterial Hypertension include Seralutinib (Gossamer Bio), BIA 5-1058 (Bial), along with others.
-
Belapectin (Galectin Therapeutics) is in the early stages of development i.e. preclinical stage for Pulmonary Arterial Hypertension treatment.
Request for the sample to get an overview of pipeline landscape @ Pulmonary Arterial Hypertension Treatment Algorithm
Pulmonary Arterial Hypertension: Overview
Pulmonary Arterial Hypertension (PAH) is a rare, progressive disorder characterized by abnormally high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery). The blood vessels that carry blood from the right side of the heart to the lungs are known as the pulmonary arteries.
Pulmonary Arterial Hypertension Symptoms
The most common Pulmonary Arterial Hypertension symptom is severe shortness of breath after exertion. Excessive fatigue, weakness, chest pain, dizzy spells, and fainting episodes are also PAH symptoms. Affected people may also have a cough, sometimes with blood (hemoptysis), an enlarged heart and liver, low blood pressure (hypotension), and hoarseness due to an enlarged pulmonary artery compressing a nerve in the chest.
Pulmonary Arterial Hypertension Treatment
The FDA has approved several drugs such as Flolan (epoprostenol sodium for injection or prostacycline), Treprostinil (Remodulin), Iloprost (Ventavis), Revatio (sildenafil), and others that are used to treat Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension Pipeline Analysis: Drug Profiles
Sotatercept: Acceleron Pharma/Bristol Myers Squibb
Product Description
Sotatercept is being tested on patients suffering from pulmonary arterial hypertension (PAH), a rare, progressive, and potentially fatal blood vessel disorder. Sotatercept is a ligand trap with high selectivity for multiple TGF-beta superfamily members.
Phase III
NCT04796337: Acceleron Pharma began the trial in May 2021. This study is being conducted to evaluate the long-term safety, tolerability, and efficacy of Sotatercept in PAH.
Pulmonary Arterial Hypertension Pipeline Therapies and Key Companies
-
Sotatercept: Acceleron Pharma/ Bristol Myers Squibb
-
Seralutinib: Gossamer Bio
-
BIA 5-1058: Bial
-
PF-06842874: Pfizer
-
AER-901: Aerami Therapeutics
-
Belapectin: Galectin Therapeutics
For more information on the emerging drugs and companies, visit Clinical Trial Design and New Therapies for Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Therapeutics Assessment
-
By Product Type
-
Monotherapy
-
Combination Therapy
-
By Stage
-
Discovery
-
Pre-Clinical
-
Phase I
-
Phase II
-
Phase III
-
Pre-registration
-
By Route of Administration
-
Inhalation
-
Intravenous
-
Oral
-
Subcutaneous
-
By Molecule Type
-
Small Molecule
-
Stem Cell Therapy
-
Gene Therapy
-
Targets
-
Immune System
-
Multiple Kinase
-
By Mechanism of Action
-
Protease Inhibitors
-
Immunomodulatory
Scope of the Report
Coverage: Global
Pulmonary Arterial Hypertension Key Players: Acceleron Pharma, Bristol Myers Squibb, Gossamer Bio, Bial, Pfizer, Aerami Therapeutics, Galectin Therapeutics, among others
Pulmonary Arterial Hypertension Pipeline Therapies: Sotatercept, Seralutinib, BIA 5-1058, PF-06842874, AER-901, Belapectin, and others
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Pulmonary Arterial Hypertension: Overview |
| 4. | Pulmonary Arterial Hypertension Pipeline Therapeutics |
| 5. | Pulmonary Arterial Hypertension Late Stage Products (Pre-registration) |
| 6. | Pulmonary Arterial Hypertension Late Stage Products (Phase III) |
| 7. | Pulmonary Arterial Hypertension Mid Stage Products (Phase II) |
| 8. | Pulmonary Arterial Hypertension Early Stage Products (Phase I) |
| 9. | Pulmonary Arterial Hypertension Pre-clinical Stage Products |
| 10. | Pulmonary Arterial Hypertension Therapeutic Assessment |
| 11. | Pulmonary Arterial Hypertension Inactive Products |
| 12. | Pulmonary Arterial Hypertension- Unmet Needs |
| 13. | Pulmonary Arterial Hypertension- Market Drivers and Barriers |
| 14. | Appendix |
| 15. | About DelveInsight |
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts
Key questions answered in the Pulmonary Arterial Hypertension Pipeline Report
-
What are the options for treating pulmonary arterial hypertension?
-
How many pharmaceutical companies are working on treatments for pulmonary arterial hypertension?
-
Which of these firms' pharmaceuticals is the most widely used?
-
How many pulmonary arterial hypertension medications does each company produce in total?
-
How many drugs are in the pipeline for pulmonary arterial hypertension that are in the early, middle, or late stages of development?
-
How many of the therapies currently in development can be used alone or in conjunction with other treatments?
-
What are the most important industry-industry and industry-academy collaborations, mergers and acquisitions, and licensing practices influencing pulmonary arterial hypertension?
Related Reports
Pulmonary Hypertension Pipeline Insights
Get a comprehensive analysis of Pulmonary Hypertension pipeline therapies and key companies including Johnson & Johnson Services, Inc., United Therapeutics Corporation, Pfizer, Inc., Acceleron Pharma, Inc., Gilead Sciences, Inc., Bayer AG., GlaxoSmithKline Plc. (GSK), among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/
